Our previous study reported that the EGFR tyrosine kinase inhibitors gefitinib and erlotinib activate autophagy in human lung cancer cells.[22] Induction of autophagy in response to these TKIs could be cytoprotective or cytodestructive, which contributes to the anticancer efficacy of these drugs as well as to drug resistance. The gene discussed is EGFR; the disease is lung carcinoma.